Organ Technologies Completes Funding for Next Growth Stage

Organ Technologies, Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Yoshio Shita; hereinafter 'Organ Technologies'), which is working on the social implementation of the world's first organ regeneration technology*1, has completed a funding round for its next growth stage.

Organ Technologies is advancing R&D for the social implementation of 'Bio-hybrid Tooth,' which aims to regenerate periodontal ligament function, and 'Third Cell (hair follicle regeneration supporting cell),' a cell derived from hair follicles, as applications of its organ regeneration technology. The company also provides R&D support services to healthcare companies using three-dimensional artificial skin.

This funding will further accelerate R&D in the regenerative medicine field, strengthen the business foundation, and expand operations both domestically and internationally.

The company will strengthen investment in the following key areas:
- Advancement of R&D and clinical development for 'Bio-hybrid Tooth'
- Strengthening of regulatory affairs and business development systems in Japan and abroad
- Establishment of production and mass production technologies
- Promotion of partnerships for global expansion
- Acceleration of hair regeneration research and business development based on the 'Third Cell'
- Expansion of the regenerative medicine pipeline, including artificial skin

'Bio-hybrid Tooth' is attracting significant interest both domestically and internationally as a next-generation bio-implant aiming to be a 'third natural tooth,' distinct from conventional implants. The company is currently working toward social implementation in Japan while also advancing regulatory and business development efforts with an eye on the future US market.

In August 2025, the company entered into a consulting agreement with QNova LifeSciences (operated by LifeSciences Regulatory Solutions, LLC), a life sciences CRO and consulting firm based in Maryland, USA. They are jointly preparing for regulatory submission to the US Food and Drug Administration (FDA) for the next-generation bio-implant.

A research group at the Southern Tohoku Medical Clinic (Location: Koriyama City, Fukushima Prefecture; Group President: Kazuo Watanabe; Chairman: Sadayoshi Watanabe; Hospital Director: Shinichi Konno; Clinic Director: Naoto Kuroda), affiliated with the Institute of Neurogenerative Diseases, and its Dental and Maxillofacial Implant Center (Director: Shohei Kasugai, Professor Emeritus at Tokyo University of Science) began a specific clinical study of 'periodontal ligament-bonded implants' on February 1, 2025. The implants were placed in four patients, and engraftment*2 has been confirmed in all cases to date.

Furthermore, the next-generation bio-implant was selected for the 'TOKYO Strategic Innovation Promotion Project' for fiscal year 2025 by the Tokyo Metropolitan Small and Medium Enterprise Support Center. The project provides subsidy support for up to three years.

In hair regeneration research, in February 2026, the company and the Organ Induction Research Team at the RIKEN Center for Biosystems Dynamics Research discovered a new 'third cell' that supports the development, growth, and regeneration of hair follicles, called the hair follicle regeneration supporting cell. This discovery was published in the scientific journal 'Biochemical and Biophysical Research Communications' and was covered by over 1,000 domestic and international media outlets, including the Associated Press. The company is also working on commercialization, such as granting a manufacturing license for cell-derived components of hair follicle regeneration supporting cells and dermal papilla cells to Kojin Bio Co., Ltd. (Headquarters: Sakado City, Saitama Prefecture; President: Takato Nakamura).

Organ Technologies aims to evolve from an R&D-focused company into a business creation company under the philosophy of 'contributing to improving people's quality of life through regenerative medical technology that harmonizes with the living body.' The company will challenge itself to create new markets while further enhancing management stability by deepening its existing businesses.

Organ Technologies management team: (Left) Miho Ogawa, (Center-left) Yoshio Shita, (Center-right) Takashi Tsuji, (Right) Yoshitaka Yamaguchi.

*1 Almost all organs develop only once during the fetal period from organ primordia composed of epithelial and mesenchymal stem cells. The process of forming a mature, fully functional organ proceeds as both epithelial and mesenchymal cell populations exchange complex molecular signals. In 2007, the Tsuji laboratory pioneered a method to reconstitute organ primordia by dissociating epithelial and mesenchymal stem cells from organ primordia and then compartmentalizing them at high density (Nature Methods 2007). This technology is called the organ primordium method. Using this method, the team has demonstrated the functional regeneration of organs such as teeth, hair follicles, salivary glands, and lacrimal glands, establishing the foundation for organ regeneration technology.

*2 Based on the progress report (published March 18, 2026) of the specific clinical study (jRCTs022240055) conducted by the Institute of Neurogenerative Diseases.

https://prtimes.jp/main/html/rd/p/000000012.000179713.html

Organ Technologies, Inc.

https://www.organ-tech.jp/